4-hydroxypyrimidine is a heterocyclic compound that serves as a building block for various important molecules. It can be synthesized through different routes, such as the reaction of 4-aminopyrimidine with nitrous acid. 4-hydroxypyrimidine exhibits diverse biological activities, including anticancer and antibacterial properties, which have led to extensive research in its potential therapeutic applications. Studies have shown that 4-hydroxypyrimidine derivatives can inhibit the growth of various cancer cell lines and possess antimicrobial activity against specific bacteria. The unique structure and biological potential of 4-hydroxypyrimidine have made it a subject of intense research, aiming to discover new and effective drugs for various diseases.'
4(3H)-pyrimidinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 20695 |
| MeSH ID | M0281044 |
| Synonym |
|---|
| AC-943 |
| 51953-18-5 |
| 4-oxypyrimidine |
| 6-hydroxypyrimidine |
| 4-pyrimidinone |
| 4-pyrimidinol (van) |
| 4-pyrimidone |
| 1h-pyrimidin-4-one |
| nsc 157911 |
| ai3-52024 |
| nsc 1575 |
| einecs 224-932-4 |
| 4-pyrimidinol |
| nsc-1575 |
| nsc1575 |
| 4-hydroxypyrimidine , |
| 4562-27-0 |
| 4-oxopyrimidine |
| deaminoisocytosine |
| 4(1h)-pyrimidinone |
| AC-907/30002018 |
| 51953-17-4 |
| 3h-pyrimidin-4-one |
| 1h-pyrimidin-6-one |
| pyrimidin-4-ol |
| inchi=1/c4h4n2o/c7-4-1-2-5-3-6-4/h1-3h,(h,5,6,7 |
| nsc157911 |
| nsc-157911 |
| 4(3h)-pyrimidinone, >=98% |
| 4(3h)-pyrimidinone, >=98.0% (nt) |
| STK409564 |
| pyrimidin-4(1h)-one |
| FT-0696311 |
| 4(3h)-pyrimidinone |
| H1000 |
| AKOS001448755 |
| A7645 |
| A7644 |
| AKOS009157155 |
| pyrimidin-4-one |
| 4-(3h)-pyrimidone |
| 4(3h)-pyrimidone |
| uraeil |
| 1h-pyrimidin-6-one;4(3h)-pyrimidone |
| A826863 |
| pyrimidin-4(3h)-one |
| unii-k43v90oy4l |
| k43v90oy4l , |
| FT-0601299 |
| FT-0648609 |
| FT-0618746 |
| AM20100167 |
| AM20100277 |
| PB32093 |
| AB00171795-03 |
| AKOS015892532 |
| mfcd00006664 |
| SY002707 |
| 4-hydroxy-pyrimidine |
| pyrimidine-4(3h)-one |
| 4-(lh)-pyrimidinone |
| DTXSID5063524 |
| W-202804 |
| W-202960 |
| A1-00389 |
| 542-27-8 |
| 3,4-dihydropyrimidin-4-one |
| Q-102029 |
| AC-25243 |
| mfcd00038024 |
| GS-5924 |
| AC-2727 |
| Z314605438 |
| F3329-0407 |
| BCP04213 |
| SY046617 |
| BCP26608 |
| BCP13987 |
| Q17572767 |
| EN300-67372 |
| STL185515 |
| SB10165 |
| 4-hydroxypyrimidine pound>>4-pyrimidinol pound>>4(3)-pyrimidone |
| CS-0019949 |
| AC8519 |
| O12062 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.75) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||